These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 22341993)

  • 1. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
    Nilsson S; Strang P; Aksnes AK; Franzèn L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland ØS
    Eur J Cancer; 2012 Mar; 48(5):678-86. PubMed ID: 22341993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
    Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
    Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
    Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; O'Bryan-Tear CG; Thuresson M; Bolstad B; Bruland ØS
    Clin Genitourin Cancer; 2013 Mar; 11(1):20-6. PubMed ID: 23021204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.
    Hartsell WF; Scott CB; Bruner DW; Scarantino CW; Ivker RA; Roach M; Suh JH; Demas WF; Movsas B; Petersen IA; Konski AA; Cleeland CS; Janjan NA; DeSilvio M
    J Natl Cancer Inst; 2005 Jun; 97(11):798-804. PubMed ID: 15928300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
    Heidenreich A; Hofmann R; Engelmann UH
    J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
    Nilsson S; Strang P; Ginman C; Zimmermann R; Edgren M; Nordström B; Ryberg M; Kälkner KM; Westlin JE
    J Pain Symptom Manage; 2005 Apr; 29(4):352-7. PubMed ID: 15857738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases.
    Hamouda WE; Roshdy W; Teema M
    Gulf J Oncolog; 2007 Jan; 1(1):35-41. PubMed ID: 20084712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
    Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
    J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer.
    Leondi AH; Souvatzoglou MA; Rapti AS; Leontopoulou SA; Papadaki EK; Datseris EI; Anagnostopoulou US; Zerva CJ
    Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):211-9. PubMed ID: 15499295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of radiotherapy for painful bone metastases during the last 12 weeks of life: results from the Dutch Bone Metastasis Study.
    Meeuse JJ; van der Linden YM; van Tienhoven G; Gans RO; Leer JW; Reyners AK;
    Cancer; 2010 Jun; 116(11):2716-25. PubMed ID: 20225326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of health-related quality of life with the European Organization for Research and Treatment of Cancer QLQ-C15-PAL after palliative radiotherapy of bone metastases.
    Caissie A; Zeng L; Nguyen J; Zhang L; Jon F; Dennis K; Holden L; Culleton S; Koo K; Tsao M; Barnes E; Danjoux C; Sahgal A; Simmons C; Chow E
    Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):125-33. PubMed ID: 21917431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22.
    Zeng L; Chow E; Bedard G; Zhang L; Fairchild A; Vassiliou V; Alm El-Din MA; Jesus-Garcia R; Kumar A; Forges F; Tseng LM; Hou MF; Chie WC; Bottomley A
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e337-42. PubMed ID: 22763028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
    J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
    Cheetham PJ; Petrylak DP
    Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy.
    Kurosaka S; Satoh T; Chow E; Asano Y; Tabata K; Kimura M; Tsumura H; Matsumoto K; Ishiyama H; Inoue Y; Hayakawa K; Baba S
    Ann Nucl Med; 2012 Jul; 26(6):485-91. PubMed ID: 22477263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.